Loading clinical trials...

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

Measurement of Pulmonary Inflammation Using 18F-NOS Positron Emission Tomography (PET/CT) in E-cigarette Users

NCT03721822•University of Pennsylvania

Summary

The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \[18F\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.

Detailed Description

This study will see how the tracer is taken up in the lungs using an imaging scan called Positron Emission Tomography / Computed Tomography (PET/CT). \[18F\]NOS is an experimental radioactive molecule used in PET imaging to measure inflammation in various organs in the body. Investigators are interested in studying whether there are differences in lung inflammation between E-cigarette users (vapers) cigarette smokers and non-smokers. \[18F\]NOS has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. The use of \[18F\]NOS in this study is allowed under an Investigational New Drug Application approved by the FDA. Investigators are also going to be studying how the information from the PET/CT scan compares to other markers of inflammation in the blood. During the PET scan, Investigators will image Brain and Lungs in order to see if there is a difference between inflammation seen in the brain and the lungs and if these differences change depending on whether a subject is a smoker, e-cigarette user or non-smoker. Consented participant in this study will undergo one (1) experimental \[18F\]NOS PET/CT scan. During the scan, PET/CT images will be taken of participant chest/torso in order to capture their lungs and a short image will be taken of their brain. Blood samples will be taken at various time points to test for markers of inflammation and to measure the concentration of the tracer in participants blood during the scan and participants will undergo some specific psychological questionnaires and tasks.

Eligibility

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Participants will be 18-45 years of age
•2. Subject must meet one of the following criteria:
•NIC vapers: current e-cigarette use of nicotine at least 5 days per week for the past year, no current combustible cigarette use, cannabis vaping, or cannabis smoking during the 30 days prior to study enrollment
•CAN vapers: current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking, or nicotine vaping during the 30 days prior to study enrollment
•Cigarette smokers: current cigarette smoking of at least 5 cigarettes per day, 4 days per week for the past year with no e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment
•Dual combustible and e-cigarette users: current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 day prior to study enrollment
•Non-Smokers: reported non-smoking history or \< 100 lifetime cigarettes, \< 100 e-cigarette use episodes, and \< 100 lifetime cannabis use episodes
•3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria

•1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening and on scan day.
•2. Current untreated and unstable diagnosis of substance use disorder, except nicotine use disorder or cannabis use disorder
•3. Positive urine drug screen for opiates, methamphetamine or cocaine at screening
•4. Current unstable and/or untreated major depression or psychotic disorder per medical record review or self-reported
•5. Use of inhaled or oral corticosteroids or anti-inflammatory medications per medical record review or self-report
•6. History of lung trauma
•7. Active (or within the previous 4 weeks of screening) lung infection or lung disease that impact uptake of \[18F\]NOS (e.g. tuberculosis, cystic fibrosis)
•8. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
•9. Any current or past medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Locations (1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

October 23, 2018

Primary Completion Date

October 23, 2026

Completion Date

October 23, 2026

Last Updated

October 3, 2025

Enrollment

100

ESTIMATED participants

Conditions

Smoking, CigaretteSmoking E-cigaretteHealthy Volunteer

Interventions

[18F]NOS

DRUG

Contacts

Erin Schubert

CONTACT

215-573-6569 erinschu@pennmedicine.upenn.edu

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITING

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Collection of Data and Samples From Healthy Donors for Use in Translational Research

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

A Study of ENX-104 in Healthy Participants

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle